VAXCYTE, INC. Capital Expenditures Incurred but Not yet Paid
VAXCYTE, INC. (PCVX) reported Capital Expenditures Incurred but Not yet Paid of $4.66 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:CapitalExpendituresIncurredButNotYetPaid · last filed 2026-08-05
- VAXCYTE, INC. capital expenditures incurred but not yet paid for the quarter ending 2026-06-30 was -$1.68M.
- VAXCYTE, INC. capital expenditures incurred but not yet paid for the quarter ending 2026-03-31 was $6.34M, a 63.10% increase year-over-year.
- VAXCYTE, INC. capital expenditures incurred but not yet paid for the quarter ending 2025-12-31 was $1.97M, a 74.25% decline year-over-year.
- VAXCYTE, INC. capital expenditures incurred but not yet paid for the quarter ending 2025-09-30 was $2.10M, a 738.80% increase year-over-year.
- VAXCYTE, INC. capital expenditures incurred but not yet paid for fiscal 2025 was $7.54M, a 42.80% decline from fiscal 2024.
- VAXCYTE, INC. capital expenditures incurred but not yet paid for fiscal 2024 was $13.18M, a 54.86% increase from fiscal 2023.
- VAXCYTE, INC. capital expenditures incurred but not yet paid for fiscal 2023 was $8.51M, a 7636.36% increase from fiscal 2022.
- VAXCYTE, INC. capital expenditures incurred but not yet paid for fiscal 2022 was $110.00K, a 85.64% decline from fiscal 2021.
| Period end | Capital Expenditures Incurred but Not yet Paid 3 month | Capital Expenditures Incurred but Not yet Paid 6 month | Capital Expenditures Incurred but Not yet Paid 9 month | Capital Expenditures Incurred but Not yet Paid 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$1.68M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $4.66M 10-Q · filed 2026-08-05 | $6.63M derived: sum of 3 quarters · filed 2026-08-05 | $8.73M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $6.34M 10-Q · filed 2026-05-06 | $8.31M derived: sum of 2 quarters · filed 2026-05-06 | $10.41M derived: sum of 3 quarters · filed 2026-05-06 | $9.99M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $1.97M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $4.07M derived: sum of 2 quarters · filed 2026-02-24 | $3.65M derived: sum of 3 quarters · filed 2026-08-05 | $7.54M 10-K · filed 2026-02-24 |
| 2025-09-30 | $2.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $1.68M derived: sum of 2 quarters · filed 2026-08-05 | $5.57M 10-Q · filed 2025-11-04 | $13.22M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | -$418.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $3.47M 10-Q · filed 2026-08-05 | $11.12M derived: sum of 3 quarters · filed 2026-08-05 | $11.37M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $3.89M 10-Q · filed 2026-05-06 | $11.54M derived: sum of 2 quarters · filed 2026-05-06 | $11.79M derived: sum of 3 quarters · filed 2026-05-06 | $3.35M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $7.65M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $7.90M derived: sum of 2 quarters · filed 2026-02-24 | -$540.00K derived: sum of 3 quarters · filed 2026-02-24 | $13.18M 10-K · filed 2026-02-24 |
| 2024-09-30 | $250.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | -$8.19M derived: sum of 2 quarters · filed 2025-11-04 | $5.53M 10-Q · filed 2025-11-04 | $13.61M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | -$8.44M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $5.28M 10-Q · filed 2025-08-06 | $13.36M derived: sum of 3 quarters · filed 2026-02-24 | $9.63M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | $13.72M 10-Q · filed 2025-05-07 | $21.80M derived: sum of 2 quarters · filed 2026-02-24 | $18.07M derived: sum of 3 quarters · filed 2026-02-24 | $22.17M derived: sum of 4 quarters · filed 2026-02-24 |
| 2023-12-31 | $8.08M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $4.35M derived: sum of 2 quarters · filed 2026-02-24 | $8.45M derived: sum of 3 quarters · filed 2026-02-24 | $8.51M 10-K · filed 2026-02-24 |
| 2023-09-30 | -$3.73M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | $376.00K derived: sum of 2 quarters · filed 2024-11-05 | $433.00K 10-Q · filed 2024-11-05 | $402.00K derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-06-30 | $4.11M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $4.16M 10-Q · filed 2024-08-06 | $4.13M derived: sum of 3 quarters · filed 2025-02-25 | $3.74M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-03-31 | $57.00K 10-Q · filed 2024-05-08 | $26.00K derived: sum of 2 quarters · filed 2025-02-25 | -$362.00K derived: sum of 3 quarters · filed 2025-02-25 | -$497.00K derived: sum of 4 quarters · filed 2025-02-25 |
| 2022-12-31 | -$31.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | -$419.00K derived: sum of 2 quarters · filed 2025-02-25 | -$554.00K derived: sum of 3 quarters · filed 2025-02-25 | $110.00K 10-K · filed 2025-02-25 |
| 2022-09-30 | -$388.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | -$523.00K derived: sum of 2 quarters · filed 2023-11-06 | $141.00K 10-Q · filed 2023-11-06 | $636.00K derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | -$135.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $529.00K 10-Q · filed 2023-08-08 | $1.02M derived: sum of 3 quarters · filed 2024-02-27 | $820.00K derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | $664.00K 10-Q · filed 2023-05-08 | $1.16M derived: sum of 2 quarters · filed 2024-02-27 | $955.00K derived: sum of 3 quarters · filed 2024-02-27 | -$107.00K derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | $495.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $291.00K derived: sum of 2 quarters · filed 2024-02-27 | -$771.00K derived: sum of 3 quarters · filed 2024-02-27 | $766.00K 10-K · filed 2024-02-27 |
| 2021-09-30 | -$204.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | -$1.27M derived: sum of 2 quarters · filed 2022-11-07 | $271.00K 10-Q · filed 2022-11-07 | $616.00K derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-06-30 | -$1.06M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $475.00K 10-Q · filed 2022-08-08 | $820.00K derived: sum of 3 quarters · filed 2023-02-27 | |
| 2021-03-31 | $1.54M 10-Q · filed 2022-05-09 | $1.88M derived: sum of 2 quarters · filed 2023-02-27 | ||
| 2020-12-31 | $345.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $494.00K 10-K · filed 2023-02-27 | ||
| 2020-09-30 | $149.00K 10-Q · filed 2021-11-10 | |||
| 2020-03-31 | $35.00K 10-Q · filed 2021-05-11 | -$141.00K derived: sum of 2 quarters · filed 2022-02-28 | $44.00K derived: sum of 3 quarters · filed 2022-02-28 | |
| 2019-12-31 | -$176.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $9.00K derived: sum of 2 quarters · filed 2022-02-28 | $21.00K 10-K · filed 2022-02-28 | |
| 2019-09-30 | $185.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | $197.00K 10-Q · filed 2020-11-12 | ||
| 2019-06-30 | $12.00K 10-Q · filed 2020-08-12 | |||
| 2018-12-31 | $3.00K 10-K · filed 2021-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |